超越KRAS：胰腺腺癌中的实用分子靶点
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma.
作者信息
Grinshpun Albert, Zarbiv Yonaton, Roszik Jason, Subbiah Vivek, Hubert Ayala
机构信息
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Melanoma Medical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Case Rep Oncol. 2019 Jan 4;12(1):7-13. doi: 10.1159/000496018. eCollection 2019 Jan-Apr.
Abstract
Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof-of-concept cases argue in favor of additional research and clinical trials' effort in this small but significant PDAC population with uncommon driver mutations.
摘要
胰腺腺癌（PDAC）预后严峻。分子和基因组分析显示，这些肿瘤绝大多数由KRAS突变驱动，目前无法进行靶向治疗。然而，在一小部分患者中发现了其他驱动突变。在此，我们报告3例转移性PDAC且KRAS野生型的患者，发现他们存在BRAF或RET致病性改变。这些患者接受了靶向治疗，疗效各异。我们认为，这些概念验证病例支持针对这一小部分具有罕见驱动突变但意义重大的PDAC人群开展更多研究和临床试验。
相似文献
1
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma.
Case Rep Oncol. 2019 Jan 4;12(1):7-13. doi: 10.1159/000496018. eCollection 2019 Jan-Apr.
2
Chemotherapy-free treatment targeting fusions and driver mutations in wild-type pancreatic ductal adenocarcinoma, a case series.
Ther Adv Med Oncol. 2024 May 19;16:17588359241253113. doi: 10.1177/17588359241253113. eCollection 2024.
3
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma.
Cancers (Basel). 2022 Dec 16;14(24):6223. doi: 10.3390/cancers14246223.
4
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Clin Cancer Res. 2023 Nov 14;29(22):4627-4643. doi: 10.1158/1078-0432.CCR-22-3930.
5
Mutant Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.
Oncologist. 2018 May;23(5):566-572. doi: 10.1634/theoncologist.2017-0467. Epub 2018 Jan 25.
6
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
Mod Pathol. 2016 Apr;29(4):402-15. doi: 10.1038/modpathol.2016.40. Epub 2016 Feb 19.
7
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
Cancer. 2020 Sep 1;126(17):3939-3949. doi: 10.1002/cncr.33038. Epub 2020 Jun 23.
8
Dysregulation of KRAS signaling in pancreatic cancer is not associated with mutations and outcome.
Oncol Lett. 2017 Nov;14(5):5980-5988. doi: 10.3892/ol.2017.6946. Epub 2017 Sep 14.
9
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Pancreas. 2012 Jul;41(5):759-66. doi: 10.1097/MPA.0b013e31823cd9df.
10
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
EBioMedicine. 2022 Mar;77:103897. doi: 10.1016/j.ebiom.2022.103897. Epub 2022 Feb 26.
引用本文的文献
1
Metastatic pancreatic cancer with activating V600E mutations: A case report.
World J Clin Cases. 2025 Jun 6;13(16):101665. doi: 10.12998/wjcc.v13.i16.101665.
2
Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma.
Front Oncol. 2024 Nov 7;14:1483306. doi: 10.3389/fonc.2024.1483306. eCollection 2024.
3
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Int J Mol Sci. 2024 Jan 28;25(3):1631. doi: 10.3390/ijms25031631.
4
Photodynamic Stromal Depletion in Pancreatic Ductal Adenocarcinoma.
Cancers (Basel). 2023 Aug 16;15(16):4135. doi: 10.3390/cancers15164135.
5
Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report.
Front Oncol. 2022 Nov 24;12:976450. doi: 10.3389/fonc.2022.976450. eCollection 2022.
6
Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report.
Front Oncol. 2022 Jan 25;11:801320. doi: 10.3389/fonc.2021.801320. eCollection 2021.
7
Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
Cold Spring Harb Mol Case Stud. 2021 Oct 19;7(5). doi: 10.1101/mcs.a006108. Print 2021 Oct.
8
Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
BMC Cancer. 2021 Jan 11;21(1):49. doi: 10.1186/s12885-020-07736-x.
9
Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy.
Case Rep Oncol. 2020 Oct 13;13(3):1239-1243. doi: 10.1159/000510096. eCollection 2020 Sep-Dec.
10
Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal.
Diagn Pathol. 2019 Jun 21;14(1):62. doi: 10.1186/s13000-019-0843-z.
本文引用的文献
1
Ex-vivo organ culture as potential prioritization tool for breast cancer targeted therapy.
Cancer Biol Ther. 2018 Aug 3;19(8):645-648. doi: 10.1080/15384047.2018.1450114. Epub 2018 Apr 13.
2
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10.
3
ClinVar: improving access to variant interpretations and supporting evidence.
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067. doi: 10.1093/nar/gkx1153.
4
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Nat Rev Clin Oncol. 2018 Mar;15(3):151-167. doi: 10.1038/nrclinonc.2017.175. Epub 2017 Nov 14.
5
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
6
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043.
7
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.
8
AACR Project GENIE: Powering Precision Medicine through an International Consortium.
Cancer Discov. 2017 Aug;7(8):818-831. doi: 10.1158/2159-8290.CD-17-0151. Epub 2017 Jun 1.
9
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2.
10
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.
Sci Rep. 2016 Oct 20;6:35848. doi: 10.1038/srep35848.
Zotero 插件